Tsingke Biotechnology Secures Nearly RMB 200 Million Series A Funding to Advance High-Throughput, High-Capacity, and Intelligent Gene Synthesis Enabling Technology Platform

Recently,Beijing Tsingke Biotechnology Co., Ltd. (“Tsingke Biotechnology”), a leading domestic synthetic biology platform company, announced the completion of its Series A financing round, raising nearly RMB 200 million.This round of financing was led by Shenzhen Investment Holdings Capital, with participation from SoftBank China Capital, Shengyu Investment, and Yueyin Medical Fund. Huasheng Capital served as the exclusive financial advisor.

Beijing Tsingke Biotechnology Co., Ltd. is a national high-tech enterprise in synthetic biology, engaged in the research and development of synthetic genomics and biosynthetic products. Its business scope covers three major areas: synthetic genomics products and services, life science research equipment and reagents, and biological manufacturing CRO/CDMO services. Headquartered in Beijing, the company operates entities and laboratories across China, with its business extending to overseas markets including the United States and Germany, serving approximately 160,000 users worldwide.

In the field of gene synthesis, Tsingke Biotechnology has extended its layout across the upstream and downstream industrial chains.The company performs approximately 200 million base syntheses annually, independently produces over 200 types of nucleic acid raw materials and consumables, developed and manufactured China’s first self-patented 768-channel pressure-blowing synthesizer, owns the country’s first independently developed intelligent gene synthesis production line, and is capable of industrial-scale gene synthesis up to 160 kb.With the rapid development of synthetic biology, Tsingke Biotechnology is poised to provide robust support to a growing number of gene synthesis customers worldwide.

Following the completion of this round of financing, the company will continue to strengthen its enabling technology platform for high-throughput, high-capacity, and intelligent gene synthesis, working closely with customers to drive in-depth exploration and industrial commercialization in the field of synthetic biology.

Looking back, 2021 was the year when synthetic biology attracted the most capital attention. According to statistics from SynbioBeta, the total funding raised in synthetic biology in 2021 is expected to surpass the sum of all funding rounds since SynbioBeta began its tracking in 2009.

Data source: Synbiobeta

Currently, synthetic biology has become one of the focal points of China’s “Dual Carbon” strategic goals. At the technical level, synthetic biology is an essential foundational technology for achieving the “Dual Carbon” targets. By enabling the efficient and comprehensive utilization of bio-based carbon resources, it helps establish a low-energy-consumption, low-pollution, and low-emission low-carbon economic model across numerous industries. Research centers and industrial clusters for synthetic biology are already taking shape in cities such as Shenzhen, Tianjin, and Shanghai. Tsingke Biotechnology Co., Ltd. has established 24 subsidiaries across China, allowing it to rapidly respond to the service needs of various R&D teams, enhance industry-wide R&D efficiency, and facilitate the rapid development of synthetic biology.

Ma Shijin, Founder, Chairman, and General Manager of Tsingke BiotechnologyHe stated, “We extend our sincere gratitude to all professional investment institutions for their support and trust in Tsingke Biotechnology. This serves as a strong endorsement of Tsingke Biotechnology’s deep commitment to the field of synthetic biology. In recent years, the Chinese government has provided substantial support to the development of the biotechnology industry, including synthetic biology, synthetic genomics, and cell and gene therapy (CGT). A series of industrial support policies have been introduced, creating a favorable environment and injecting robust momentum into the growth of the biotech sector.”Gene synthesis is one of the core enabling technologies in synthetic biology, playing a crucial role in supporting and driving its development. As a full-chain enterprise and solution provider in gene synthesis—integrating synthetic raw materials, intelligent and high-efficiency synthesis systems, and synthesis services—Tsingke Biotechnology Co., Ltd. has established a closed-loop business model encompassing “design, synthesis, assembly, and testing.” The company provides comprehensive products and services to biomedical enterprises, research institutes, and academic institutions in fields such as synthetic biological manufacturing, nucleic acid therapeutics, and cell and gene therapy (CGT).“This round of financing is of great significance for the company to further expand its synthesis capacity, accelerate the R&D progress of high-throughput synthesis systems, promote technology transfer and new product development, etc. We would like to express our sincere gratitude to all participating institutions once again.”

Dr. Liu Haijie, Healthcare Investment Team, Shenzhen Capital Groupstated: “We are honored to participate in this round of financing for Tsingke Biotechnology. The synthetic biology industry is currently experiencing rapid growth, which is inseparable from robust support from upstream R&D services. Tsingke Biotechnology offers comprehensive products and services with rapid response times, and has established close collaborative relationships with numerous research institutions. The company’s team boasts strong professional backgrounds, extensive R&D experience, seamless collaboration, and high execution efficiency. We look forward to Tsingke Biotechnology continuing its in-depth cooperation with various research institutions to drive the development of synthetic biology in China.”

Zhao Gang, Partner at SoftBank China Capital“SoftBank China Capital continues to closely monitor the global development of synthetic biology. As the throughput and cost-efficiency of gene synthesis continue to improve, and as demand for related technical services from companies producing synthetic biology products grows, market demand for gene synthesis services and products is expected to increase significantly. Supported by its dual platforms for gene synthesis design services and gene synthesis equipment manufacturing, Tsingke Biotechnology will accelerate the R&D of innovative technologies and core products in synthetic biology, thereby expanding its strategic growth opportunities. We are honored to participate in this round of financing for Tsingke Biotechnology.”

Shen Qin, Partner at Shengyu Investmentstated, “We have long focused on outstanding companies in the synthetic biology sector. Tsingke Biotechnology boasts a highly capable and exceptional team, has achieved significant breakthroughs in long-fragment gene synthesis, rapidly advanced its automation equipment, and continuously iterated and enhanced its operational capabilities. We are delighted to partner with Tsingke Biotechnology to jointly build a next-generation leading enterprise in synthetic biology.”

Xiong Shuirou, Partner at Yuyin Medical Fundstated: “We are highly optimistic about the prospects of synthetic biology. Tsingke Biotechnology Co., Ltd. boasts a comprehensive scientific research service platform, with a solid foundation and extensive experience in gene synthesis, sequencing, and primer synthesis. The company is equipped with an outstanding team that possesses rich experience in R&D, process development, production, operations, and management. We look forward to the rapid commercialization of Tsingke Biotechnology’s R&D achievements in the field of synthetic biology.”

Dr. Duan Zhigang, Partner at Huasheng Capital“The statement read: ‘Tsingke Biotechnology is a leading enterprise in China that covers the entire industrial chain of gene synthesis. The company boasts exceptional technical strength, solid technological reserves, and a robust service network system. As humanity begins to leverage synthetic biology to proactively design and create new production methods on a large scale, striding confidently into the “Era of Green Manufacturing,” gene synthesis, as a core enabling technology, will serve as a powerful driving engine. Huasheng Capital is honored to have served as the exclusive financial advisor for Tsingke Biotechnology’s current round of financing. In the future, we will continue to support Tsingke Biotechnology’s growth over the long term and provide high-quality services to companies in China’s synthetic biology sector.’”